Jadranka Dejanović
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jadranka Dejanović has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Anastazija Stojšić-Milosavljević
The Institute for Cardiovascular Diseases of Vojvodina
1 shared publication - Dragan Tešić
Faculty of Medicine University of Novi
1 shared publication - Dragica Andrić
Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia
1 shared publication Milan Nedeljković
Clinical Center of Serbia Cardiology Clinic Belgrade Serbia
1 shared publication- Milenko Čanković
Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
1 shared publication - Milovan Petrovic
Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia
1 shared publication
Latest Publications
- Open Access
- 1 January 2021
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Srce i krvni sudovi
- Vol. 40 (2) , 91-93
Heart failure and malignancies
In recent years, cardiovascular diseases (CVD) and cancer have been the leading causes of death. Malignant diseases and heart failure are the two most common diseases in the elderly population and are responsible for most deaths. Higher general mortality has also been observed in patients with associated malignancy and heart failure, which may be partly due to the fact that optimal treatment of none of these diseases can be performe. These two conditions share a number of risk factors, such as obesity, hypertension, smoking and hyperglycaemia, but also pathophysiological mechanisms, which were considered characteristic for heart failure only, which raises the suspicion that its presence alone may be a risk factor for cancer development. It has been shown that patients with heart failure have a higher incidence of malignancies compared to the general population. On the other hand, patients with malignancy have a higher risk of CV death and a worse prognosis compared to the general population. Because of this, it is important to monitor patients with heart failure, to make early diagnosis of malignancy, adequate treatment of both comorbidities and long-term observation by cardiologists and oncologists together.
- 1 January 2021
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Srce i krvni sudovi
- Vol. 40 (2) , 91-93
Open AccessHeart failure and malignancies
In recent years, cardiovascular diseases (CVD) and cancer have been the leading causes of death. Malignant diseases and heart failure are the two most common diseases in the elderly population and are responsible for most deaths. Higher general mortality has also been observed in patients with associated malignancy and heart failure, which may be partly due to the fact that optimal treatment of none of these diseases can be performe. These two conditions share a number of risk factors, such as obesity, hypertension, smoking and hyperglycaemia, but also pathophysiological mechanisms, which were considered characteristic for heart failure only, which raises the suspicion that its presence alone may be a risk factor for cancer development. It has been shown that patients with heart failure have a higher incidence of malignancies compared to the general population. On the other hand, patients with malignancy have a higher risk of CV death and a worse prognosis compared to the general population. Because of this, it is important to monitor patients with heart failure, to make early diagnosis of malignancy, adequate treatment of both comorbidities and long-term observation by cardiologists and oncologists together.
- 1 January 2020
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Srce i krvni sudovi
- Vol. 39 (3) , 27-30
Treatment challenges in a very high-risk diabetic patient with coronary artery disease
We present 58-year woman with T2 diabetes mellitus and multiple cardiovascular risk factors who was addmited to our clinic due to unstabile angina. Coronary angiography revealed bifurcation lesion of medial left anterior descending coronary artery (LAD) with 90% stenosis and first diagonal branch (D1) with a vessel diameter of 2 mm, and percutaneous coronary intervention (PCI) with implantation of one drug eluting stent (DES) in medial LAD was performed. During the follow-up optimal blood pressure control was achieved with combination of antihypertensive drugs and poor glycaemic control was managed with adding empagliflosin to metformin. Trimetazidine was initiated as a second-line treatment to reduce angina symptoms. Repeated coronary angiography due to angina one year later showed patent stent in mid LAD, but gracile periphery of LAD and D1 branch, not suitable for PCI. Optimal medical tretment was indicated. Lifestyle changes were also recommended. Ezetimibe was added to statin therapy due to high levels of LDL cholesterol. Further multifactorial aproach and tighter control of risk factors is needed in order to prevent other vascular complications in this patient.
- 1 January 2020
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Srce i krvni sudovi
- Vol. 39 (3) , 27-30
Treatment challenges in a very high-risk diabetic patient with coronary artery disease
We present 58-year woman with T2 diabetes mellitus and multiple cardiovascular risk factors who was addmited to our clinic due to unstabile angina. Coronary angiography revealed bifurcation lesion of medial left anterior descending coronary artery (LAD) with 90% stenosis and first diagonal branch (D1) with a vessel diameter of 2 mm, and percutaneous coronary intervention (PCI) with implantation of one drug eluting stent (DES) in medial LAD was performed. During the follow-up optimal blood pressure control was achieved with combination of antihypertensive drugs and poor glycaemic control was managed with adding empagliflosin to metformin. Trimetazidine was initiated as a second-line treatment to reduce angina symptoms. Repeated coronary angiography due to angina one year later showed patent stent in mid LAD, but gracile periphery of LAD and D1 branch, not suitable for PCI. Optimal medical tretment was indicated. Lifestyle changes were also recommended. Ezetimibe was added to statin therapy due to high levels of LDL cholesterol. Further multifactorial aproach and tighter control of risk factors is needed in order to prevent other vascular complications in this patient.